Michael D. Cameron

Scripps Research Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

54h-index11.3kcitations430works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(27), Lung Cancer Treatments and Mutations(24), Cancer, Hypoxia, and Metabolism(21), Neuropeptides and Animal Physiology(21), Melanoma and MAPK Pathways(17)

Publications430 total

Structural determinants of non-covalent PPARγ inverse agonism and their therapeutic implications
Nature Communications·2025Open Access
GTP release-selective agonists prolong opioid analgesic efficacy
Nature·2025· 3 citedOpen Access
Combining spironolactone to antiretroviral therapy accelerates HIV decay in humanized mice
UNC Libraries·2025Open Access
Figure S6 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Data from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Tables S1-S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Supplementary Methods S1 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S1 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S5 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S9 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S12 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S7 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S8 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S4 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S10 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S2 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S3 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S13 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Combining spironolactone to antiretroviral therapy accelerates HIV decay in humanized mice
Emerging Microbes & Infections·2025· 1 citedOpen Access
page 1 of 22Next →

Frequent Co-authors

Theodore M. Kamenecka(7), Thomas D. Bannister(7), Laura Bohn(6), Derek R. Duckett(6), Matthew D. Disney(6), Claudia Ruiz(6), Cullen L. Schmid(5), Nathanael S. Gray(5), Stephan C. Schürer(4), Pasi A. Jänne(4), William Roush(4), Steven D. Aust(4), Lin Li(4), Philip V. LoGrasso(4), Laura A. Solt(3), Douglas J. Kojetin(3), Andrew A. Butler(3), Thomas P. Burris(3), Nicole Kennedy(3), Kimberly M. Lovell(3)